ClinicalTrials.gg

Program

tibulizumab

Also written as “LY3090106”, “Tibulizumab Dose A” and “Tibulizumab Dose B”.

Its studies are mostly in Hidradenitis Suppurativa · Scleroderma, Systemic · Sjogren's Syndrome · Arthritis, Rheumatoid, led by 2 companies.

Furthest: phase 2, since Aug 15, 20135 company-led studies, 2 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly30 open or runningphase 1since Aug 15, 2013Aug 15, 2013none ahead
Zura Bio22 open or runningphase 2since Feb 7, 2025Feb 7, 2025May 2027phase 2 · NCT06843239

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 15, 2013First study: phase 1 study in Arthritis, RheumatoidNew to Eli LillyEli Lilly · NCT01925157 · 43 enrolled · Bulgaria, Moldova, Republic of, Poland and more
  2. Nov 24, 2015Phase 1 study in Sjogren's SyndromeEli Lilly · NCT02614716 · 32 enrolled · United States, Bulgaria, Georgia and more
  3. Nov 8, 2018Phase 1 study in HealthyEli Lilly · NCT03736772 · 30 enrolled · United States
  4. Feb 7, 2025Zura Bio's first study: phase 2 study in Scleroderma, SystemicNew to Zura BioZura Bio · NCT06843239 · 80 enrolled · United States, Argentina, Chile and more
  5. May 19, 2025Phase 2 study in Hidradenitis SuppurativaZura Bio · NCT06993610 · 247 enrolled · United States, Canada, Germany and more

Ahead

  1. May 2027Primary completion: phase 2 study in Scleroderma, SystemicZura Bio · NCT06843239

TargetBeta

“Tumor necrosis factor ligand superfamily member 13B inhibitor; Interleukin 17A inhibitor”ChEMBL 37, by rule

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06993610Hidradenitis Suppurativa · United States, Canada, Germany and more2Active, not recruitingZura BioSep 18, 2026247
NCT06843239Scleroderma, Systemic · United States, Argentina, Chile and more2Active, not recruitingZura BioMay 202780
NCT03736772Healthy · United States1CompletedEli LillyMar 13, 201930
NCT02614716Sjogren's Syndrome · United States, Bulgaria, Georgia and more1CompletedEli LillySep 5, 201832
NCT01925157Arthritis, Rheumatoid · Bulgaria, Moldova, Republic of, Poland and more1CompletedEli LillyJan 201543

How it is read

Names in the registry

  • “LY3090106”, 2 entries
  • “Tibulizumab Dose A”, 1 entry
  • “Tibulizumab Dose B”, 1 entry
  • “Tibulizumab”, 1 entry
  • “LY3090106 - SQ”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.